New registry tracks Odevixibat's Long-Term impact on rare liver disease

NCT ID NCT07185919

Recruiting now Disease control Sponsor: Ipsen Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 04, 2026 · Updated 3 times

Summary

This registry will follow 10 people with progressive familial intrahepatic cholestasis (PFIC) in South Korea who are taking odevixibat (Bylvay). The goal is to see how safe and effective the drug is over the long term in real-world use. Researchers will track side effects and how long patients go without needing surgery or a liver transplant.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: odevixibat (Bylvay)
What this could lead to: If successful, this registry could confirm that odevixibat is safe and effective for long-term use in PFIC patients, supporting its continued use as a treatment option.
What could go wrong: This is a small registry (10 people) in one country, not a controlled trial. It tracks real-world use, so results may not prove cause and effect or apply to all PFIC patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Cholestasis, progressive familial intrahepatic 1 progressive familial intrahepatic cholestasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS

Contacts and locations

Locations

Pusan National University Yangsan Hospital
RECRUITING

Gyeongsang, South Korea
Seoul National University Hospital
ACTIVE_NOT_RECRUITING

Seoul, South Korea
Severance Hospital, Yonsei University Health System
RECRUITING

Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.